Republic of KoreaTuberculosis profile
Population  2014 50 million
Estimates of TB burden * 2014 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 1.9 (1.8–2.1) 3.8 (3.6–4.1)
Mortality (HIV+TB only) <0.01 (<0.01–0.013) 0.02 (0.01–0.03)
Prevalence  (includes HIV+TB) 50 (18–100) 101 (35–199)
Incidence  (includes HIV+TB) 43 (41–46) 86 (81–91)
Incidence (HIV+TB only) 0.19 (0.15–0.23) 0.37 (0.3–0.45)
         
Case detection, all forms (%) 93 (88–99)    
Estimates of MDR-TB burden * 2014   New   Retreatment
% of TB cases with MDR-TB 2.7 (2.1–3.4) 14 (10–19)
MDR-TB cases among notified pulmonary
TB cases
760 (590–960) 1 000 (740–1 400)
TB case notifications 2014 New ** Relapse
Pulmonary, bacteriologically confirmed 18 784   2 705
Pulmonary, clinically diagnosed 9 350   1 665
Extrapulmonary 6 987   699
       
Total new and relapse 40 190    
Previously treated, excluding relapses 2 898    
Total cases notified 43 088    
Among 39 938 new and relapse cases:
177 (<1%) cases aged under 15 years; male:female ratio: 1.4
Reported cases of RR-/MDR-TB 2014 New Retreatment Total **
Cases tested for RR-/MDR-TB 19 412 (103%) 4 299 (54%) 23 793
Laboratory-confirmed RR-/MDR-TB cases     1 172
Patients started on MDR-TB treatment ***     856
TB/HIV 2014 Number (%)
TB patients with known HIV status    
HIV-positive TB patients    
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT)    
HIV-positive TB patients on antiretroviral therapy (ART)    
HIV-positive people screened for TB    
HIV-positive people provided with IPT    
Treatment success rate and cohort size (%) Cohort
New and relapse cases registered in 2013 (82) 40 794
Previously treated cases, excluding relapse, registered in 2013 (74) 3 257
HIV-positive TB cases, all types, registered in 2013    
RR-/MDR-TB cases started on second-line treatment in 2012 (60) 1 212
XDR-TB cases started on second-line treatment in 2012 (41) 158
Laboratories 2014  
Smear (per 100 000 population) 1.2
Culture (per 5 million population) 9.8
Drug susceptibility testing (per 5 million population) 1.1
Sites performing Xpert MTB/RIF 60
Is second-line drug susceptibility testing available? Yes, in country
Financing TB control 2015  
National TB programme budget (US$ millions) 34
% Funded domestically 100%
% Funded internationally  
% Unfunded 0%
* Ranges represent uncertainty intervals
** Includes cases with unknown previous TB treatment history
*** Includes patients diagnosed before 2014 and patients who were not laboratory-confirmed as having
RR-/MDR-TB
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
   Prevalence

(Rate per 100 000 population per year)
Incidence graph
   Notified (new and relapse)   Incidence
   Incidence (HIV+TB only)

(Number of patients)
CPT ART graph
   HIV-positive TB patients
   on CPT   on ART

Treatment success rate (%)
tx success graph
   New   Retreatment
   New and relapse   Retreatment, excluding
relapse
   HIV-positive   RR-/MDR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Funded domestically__Funded internationally
__Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2016-02-06 Data: www.who.int/tb/data